Compare Chewy Inc (CHWY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chewy Inc vs Novo Nordisk A/S — how do they compare? Chewy Inc trades at $22.38 (market cap $9.20B), while Novo Nordisk A/S trades at $46.46 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 22.6× Chewy Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Chewy Inc pays none. Which is the better fit depends on your goals.
| CHWY | NVO | |
|---|---|---|
Market Cap | $9.20B | $207.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $42.33 | $63.98 |
52-Week Low | $17.51 | $35.29 |
Enterprise Value | $9.16B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CHWY trades at $22.38, down 0.93% on the day, with a bearish technical signal and neutral oscillators. Revenue grew to $11.86B in 2025, with net income surging to $392.74M, though margins remain thin. Recent news highlights insider selling and mixed institutional moves, while analyst consensus is strongly bullish with an $33.82 price target.
The stock offers growth potential from recurring revenue and market expansion but faces risks from competition and volatile earnings. With high valuation multiples and bearish technicals, near-term pressure may persist, but long-term prospects hinge on sustained profitability and execution against rivals like Amazon.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
